Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
- DOI
- 10.1016/s1470-2045(25)00329-8
- Published
- 2025-09
- Container
- The Lancet Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-25-00329-8,
title = {Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis},
author = {Yichen Zhang and Dingyi Chen and Mengyuan Fu and Luwen Shi and Huseyin Naci and Anita K Wagner and Joseph S Ross and Xiaodong Guan},
year = {2025},
journal = {The Lancet Oncology},
doi = {10.1016/s1470-2045(25)00329-8},
url = {https://doi.org/10.1016/s1470-2045(25)00329-8}
}RIS
TY - JOUR TI - Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis AU - Yichen Zhang AU - Dingyi Chen AU - Mengyuan Fu AU - Luwen Shi AU - Huseyin Naci AU - Anita K Wagner AU - Joseph S Ross AU - Xiaodong Guan PY - 2025 JO - The Lancet Oncology DO - 10.1016/s1470-2045(25)00329-8 UR - https://doi.org/10.1016/s1470-2045(25)00329-8 ER -
APA
Zhang, Y., Chen, D., Fu, M., Shi, L., Naci, H., Wagner, A. K., Ross, J. S., & Guan, X. (2025). Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(25)00329-8
Source records
- crossref · retrieved 2026-09-26T15:55:27.608Z